A phase II Clinical Trial of PXD101 in Patients with Advanced Multiple Myeloma

Mise à jour : Il y a 5 ans
Référence : EUCTR2004-002054-55

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

• In patients with advanced myeloma to assess the efficacy of PXD101 treatment (as measured by response rate (CR, PR, MR, NC/SD, PD) using the response criteria of Bladé et al Br.J.Haematol. 1998, 102: 1115-23)).


Critère d'inclusion

  • Patients in relapse from prior treatment, with histologically and otherwise verified diagnosis of multiple myeloma